Betty C. Pang

Regulatory clients include:

• Ceribell
• Cerula Care
• Eargo
• Eleusis
• Elevar Therapeutics
• Galen Healthcare
• Health Outlook
• Healthy Longevity Clinic
• Inari
• Neuralink
• Oscar Health
• P3 Health Partners
• Perry Health
• Praxis Precision Medicines
• RIPPL Care
• Tenet
• The Cooper Companies
• The Oncology Institute

Ms. Pang’s transactional work includes:

Capital Markets

• Aimmune Therapeutics in its US$160 million initial public offering
• Aligos Therapeutics in its US$173 million initial public offering
• Angion Biomedical in its US$117 million initial public offering
• Arcutis Biotherapeutics in its US$183 million common stock offering
• Ascendis Pharma in its US$500 million initial public offering and subsequent US$500 million convertible notes offering
• Corvus Pharmaceuticals in its US$60 million follow-on offering
• CytomX Therapeutics in its US$116.9 million initial public offering and follow-on offering
• Gritstone Oncology in its US$74.8 million offering
• Imago BioSciences in its US$134.4 million initial public offering
• Oscar Health in its US$1.44 billion initial public offering
• Prometheus Biosciences in its US$218 million initial public offering
• Prothena in its US$72.6 million offering
• Revolution Medicines in its:
  • US$230 million public offering
  • US$300 million common stock offering
• Rhythm Pharmaceuticals in its US$172 million common stock offering
• Sana Biotechnology in its US$675 initial public offering
• Teladoc in its US$180 million initial public offering
• Numerous underwriters in various offerings, including:
  • Aclaris Therapeutics’ US$25 million at-the-market offering
  • Alpine Immune Sciences' US$100 million public offering
  • Aspira Women’s Health’s US$52 million common stock offering
  • Chinook Therapeutics’ US$105 million public offeringEliem Therapeutics’ initial public offering
  • Halozyme Therapeutics’ US$700 million convertible senior notes offering
  • Instil Bio’s US$320 million initial public offering
  • Minerva Surgical’s US$75 million initial public offering
  • Petco’s US$279 initial public offering
  • Sientra’s US$42 million common stock offering
  • Vor Biopharma’s US$203 million initial public offering

Mergers and Acquisitions

• Bonti in its US$195 million sale to Allergan
• CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
• Eleusis in its US$446 million business combination with Silver Spike Acquisition Corp.
• IIImago BioSciences in its pending US$1.35 billion acquisition by Merck
• Khosla Ventures Acquisition Co. in its US$2.25 billion business combination with Valo Health
• KKR in its:
  • US$1.4 billion acquisition of PharMerica
  • US$354 million acquisition of Covenant Surgical Partners
• Leonard Green & Partners L.P. in its US$363 million acquisition of Prospect Medical Holdings
• North American Science Associates (NAMSA) in its US$43.5 million acquisition of American Preclinical Services, LLC
• Pionyr Immunotherapeutics in its US$275 million sale to Gilead Sciences
• Preventice Solutions in its US$1.23 billion sale to Boston Scientific

Finance

• Bank of America and Merrill Lynch, Fenner, Pierce & Smith in the US$3 billion term loan and revolving credit facilities in connection with Gilead Science’s US$11.2 billion acquisition of Pharmasset, a clinical stage pharmaceutical company focused primarily on developing oral therapeutics for the treatment of hepatitis C
• Deutsche Bank in the incremental term loan and revolving credit facility in connection with Endo Limited's acquisition of Par Pharmaceutical Holdings, a specialty pharmaceutical company
• Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
• JPMorgan in the:
  • US$3.65 billion term loan and revolving credit facility for PPD, a global contract research organization that provides drug discovery, clinical development, lifecycle management, and laboratory services, to refinance existing debt
  • US$38.3 billion term loan facilities in connection with Takeda Pharmaceutical Company Limited’s acquisition of Shire plc, an Ireland-based biopharmaceutical company
• SLR Capital Partners in the US$300 million debt facilities for Outset Medical